CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is -H;

R^2 is -H, -F, or -Cl;

R^{21} is -H, -F, or -Cl;

R^3 is -H, -F, or -Cl;

R^{4a} and R^{4b} are each independently -H, halogen, -OH, or C_{1-6} alkyl;

Ring A is C_{3-10} cycloalkyl or heterocyclyl;

n is 0, 1, 2, 3, or 4;

each R^5 is independently halogen, =O, $=CH_2$, -CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, -O-(R^{51}), or -N(R^{51})(R^{52});

wherein each $=CH_2$, alkyl, alkenyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R^5 is optionally substituted with one to four R^{5a}, which may be the same or different;

each R^{5a} is independently halogen, -CN, C_{1-6} alkyl, C_{6-10} aryl, or -O(R^{51});

wherein each R^{51} and R^{52}, which may be the same or different, is independently -H, C_{1-6} alkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl;

R^6 is -H, C_{1-8}alkyl, C_{1-6} haloalkyl, C_{3-12} cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R^{1a})(R^{1b}), -S(O)(NR^{1a})(R^{1b}), -C(O)R^{1c}, -S(O_2)R^{1c}, or -C(O)OR^{1d},

wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^6 is each optionally substituted with one to four Z^1, which may be the same or different;

R^7 is -H, C_{1-8}alkyl, C_{1-6} haloalkyl, C_{3-12}cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R^{2a})(R^{2b}), -S(O)(NR^{2a})(R^{2b}), -C(O)R^{2c}, S(O_2)R^{2c}, or -C(O)OR^{2d},

wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^7 is each optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S;

each Z^1, Z^2, or Z^3 is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, =O, imino, -NO_2, -N_3, -CN, -O-R^{3a}, -C(O)-R^{3a}, -C(O)O-R^{3a}, -C(O)-N(R^{3a})(R^{3b}), -N(R^{3a})(R^{3b}), -N(R^{3a})$_2$(R^{3b})$^+$,-N(R^{3a})C(O)-R^{3b}, -N(R^{3a})C(O)O-R^{3b}, -N(R^{3a})C(O)N(R^{3b})(R^{3c}), -N(R^{3a})S(O_2)(R^{3b}), -NR^{3a}S(O_2)N(R^{3b})(R^{3c}), -NR^{3a}S(O_2)O(R^{3b}), -OC(O)R^{3a}, -OC(O)OR^{3a}, -OC(O)-N(R^{3a})(R^{3b}), -S-R^{3a}, -S(O)R^{3a}, -S(O)(NH)R^{3a}, -S(O_2)R^{3a}, -S(O_2)N(R^{3a})(R^{3b}), -S(O)(NR^{3a})R^{3b}, -S(O)(NR^{3a})N(R^{3b})(R^{3c}), -SF_5, or -Si(R^{3a})$_3$;

wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z^1, Z^2, or Z^3 is each optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, =O, -NO_2, -CN, -N_3, -O-R^{3a}, -C(O)R^{3a}, -C(O)O-R^{3a}, -C(O)N(R^{3a})(R^{3b}), -N(R^{3a})(R^{3b}), -N(R^{3a})$_2$(R^{3b}) $^+$, -N(R^{3a})-C(O)R^{3b}, -N(R^{3a})C(O)O(R^{3b}), -N(R^{3a})C(O)N(R^{3b})(R^{3c}), -N(R^{3a})S(O_2)(R^{3b}), -N(R^{3a})S(O_2)-N(R^{3b})(R^{3c}), -N(R^{3a})S(O_2)O(R^{3b}), -OC(O)R^{3a}, -OC(O)OR^{3a}, -OC(O)-N(R^{3a})(R^{3b}), -S-R^{3a}, -S(O)R^{3a}, -S(O)(NH)R^{3a}, -S(O_2)R^{3a}, -S(O_2)N(R^{3a})(R^{3b}), -S(O)(NR^{3a})R^{3b}, or -Si(R^{3a})$_3$;

wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is each optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -OH, -CN, -NO_2, -NH_2, -N_3, -SH,

-O(C_{1-9} alkyl), -O(C_{1-8} haloalkyl), -O(C_{2-6} alkenyl), -O(C_{2-6} alkynyl), -O(C_{3-15} cycloalkyl), -O(heterocyclyl), -O(C_{6-10} aryl), -O(heteroaryl), -NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{2-6} alkenyl), -NH(C_{2-6} alkynyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(C_{6-10} aryl), -NH(heteroaryl), -N(C_{1-9} alkyl)$_2$, -N(C_{1-8} haloalkyl)$_2$, -N(C_{2-6} alkenyl)$_2$, -N(C_{2-6} alkynyl)$_2$, -N(C_{3-15} cycloalkyl)$_2$, -N(heterocyclyl)$_2$, -N(C_{6-10} aryl)$_2$, -N(heteroaryl)$_2$, -N(C_{1-9} alkyl)(C_{1-8} haloalkyl), -N(C_{1-9} alkyl)(C_{2-6} alkenyl), -N(C_{1-9} alkyl)(C_{2-6} alkynyl), -N(C_{1-9} alkyl)(C_{3-15} cycloalkyl), -N(C_{1-9} alkyl)(heterocyclyl), -N(C_{1-9} alkyl)(C_{6-10} aryl), -N(C_{1-9} alkyl)(heteroaryl), -C(O)(C_{1-9} alkyl), -C(O)(C_{1-8} haloalkyl), -C(O)(C_{2-6} alkenyl), -C(O)(C_{2-6} alkynyl), -C(O)(C_{3-15} cycloalkyl), -C(O)(heterocyclyl), -C(O)(C_{6-10} aryl), -C(O)(heteroaryl), -C(O)O(C_{1-9} alkyl), -C(O)O(C_{1-8} haloalkyl), -C(O)O(C_{2-6} alkenyl), -C(O)O(C_{2-6} alkynyl), -C(O)O(C_{3-15} cycloalkyl), -C(O)O(heterocyclyl), -C(O)O(C_{6-10} aryl), -C(O)O(heteroaryl), -C(O)NH_2, -C(O)NH(C_{1-9} alkyl), -C(O)NH(C_{1-8} haloalkyl), -C(O)NH(C_{2-6} alkenyl), -C(O)NH(C_{2-6} alkynyl), -C(O)NH(C_{3-15} cycloalkyl), -C(O)NH(heterocyclyl), -C(O)NH(C_{6-10} aryl), -C(O)NH(heteroaryl), -C(O)N(C_{1-9} alkyl)$_2$, -C(O)N(C_{1-8} haloalkyl)$_2$, -C(O)N(C_{2-6} alkenyl)$_2$, -C(O)N(C_{2-6} alkynyl)$_2$, -C(O)N(C_{3-15} cycloalkyl)$_2$, -C(O)N(heterocyclyl)$_2$, -C(O)N(C_{6-10} aryl)$_2$, -C(O)N(heteroaryl)$_2$, -NHC(O)(C_{1-9} alkyl), -NHC(O)(C_{1-8} haloalkyl), -NHC(O)(C_{2-6} alkenyl), -NHC(O)(C_{2-6} alkynyl), -NHC(O)(C_{3-15} cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(C_{6-10} aryl), -NHC(O)(heteroaryl), -NHC(O)O(C_{1-9} alkyl), -NHC(O)O(C_{1-8} haloalkyl), -NHC(O)O(C_{2-6} alkenyl), -NHC(O)O(C_{2-6} alkynyl), -NHC(O)O(C_{3-15} cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(C_{6-10} aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C_{1-9} alkyl), -NHC(O)NH(C_{1-8} haloalkyl), -NHC(O)NH(C_{2-6} alkenyl), -NHC(O)NH(C_{2-6} alkynyl), -NHC(O)NH(C_{3-15} cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C_{6-10} aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C_{1-9} alkyl), -N(C_{1-9} alkyl)(S(O)(C_{1-9} alkyl), -S(C_{1-9} alkyl), -S(C_{1-8} haloalkyl), -S(C_{2-6} alkenyl), -S(C_{2-6} alkynyl), -S(C_{3-15} cycloalkyl), -S(heterocyclyl), -S(C_{6-10} aryl), -S(heteroaryl), -S(O)N(C_{1-9} alkyl)$_2$, -S(O)(C_{1-9} alkyl), -S(O)(C_{1-8} haloalkyl), -S(O)(C_{2-6} alkenyl), -S(O)(C_{2-6} alkynyl), -S(O)(C_{3-15} cycloalkyl), -S(O)(heterocyclyl), -S(O)(C_{6-10} aryl), -S(O)(heteroaryl), -S(O)$_2$(C_{1-9} alkyl), -S(O)$_2$(C_{1-8} haloalkyl), -S(O)$_2$(C_{2-6} alkenyl), -S(O)$_2$(C_{2-6} alkynyl), -S(O)$_2$(C_{3-15} cycloalkyl), -S(O)$_2$(heterocyclyl), -S(O)$_2$(C_{6-10} aryl), -S(O)$_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -S(O)$_2$NH(C_{1-9} alkyl), or -S(O)$_2$N(C_{1-9} alkyl)$_2$;

wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1b} is optionally substituted with one to three C_{1-9} alkyl, C_{1-8} haloalkyl, halogen, -OH, $-NH_2$, $-O(C_{1-9}$ alkyl), $-O(C_{1-8}$ haloalkyl), $-O(C_{3-15}$ cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), $-NH(C_{1-9}$ alkyl), $-NH(C_{1-8}$ haloalkyl), $-NH(C_{3-15}$ cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), $-N(C_{1-9}$ alkyl)$_2$, $-N(C_{3-15}$ cycloalkyl)$_2$, $-NHC(O)(C_{1-8}$ haloalkyl), $-NHC(O)(C_{3-15}$ cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), $-NHC(O)O(C_{1-9}$ alkyl), $-NHC(O)O(C_{1-8}$ haloalkyl), $-NHC(O)O(C_{2-6}$ alkynyl), $-NHC(O)O(C_{3-15}$ cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), $-NHC(O)NH(C_{1-9}$ alkyl), $S(O)_2(C_{1-9}$ alkyl), $-S(O)_2(C_{1-8}$ haloalkyl), $-S(O)_2(C_{3-15}$ cycloalkyl), $-S(O)_2$(heterocyclyl), $-S(O)_2$(aryl), $-S(O)_2$(heteroaryl), $-S(O)(NH)(C_{1-9}$ alkyl), $-S(O)_2NH(C_{1-9}$ alkyl), or $-S(O)_2N(C_{1-9}$ alkyl)$_2$;

each R^{1a}, R^{1b}, R^{1c}, R^{1d}, R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{3a}, R^{3b}, and R^{3c} is independently -H, C_{1-9} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R^{1a}, R^{1b}, R^{1c}, R^{1d}, R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{3a}, R^{3b}, and R^{3c} is each optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each aryl of the compound of Formula (I) unless otherwise specified is C_{6-10} aryl;

wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S;

wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein

R^1 is -H;

R^2 is -H, -F, or -Cl;

R^3 is -H, -F, or -Cl;

R^{4a} and R^{4b} are each independently -H, halogen, -OH, or C_{1-6} alkyl;

Ring A is C_{3-10} cycloalkyl or heterocyclyl;

n is 0, 1, 2, 3, or 4;

each R^5 is independently halogen, =O, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{1-6} alkoxy, C_{3-6} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, -O-(R^{51}), or -N(R^{51})(R^{52});

wherein each alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, heterocyclyl, aryl, or heteroaryl of R^5 is optionally substituted with one to four R^{5a}, which may be the same or different;

each R^{5a} is independently halogen, -CN, C_{1-6} alkyl, C_{6-10} aryl, or -O(R^{51});

wherein each R^{51} and R^{52}, which may be the same or different, is independently -H, C_{1-6} alkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl;

R^6 is -H, C_{1-8}alkyl, C_{1-6} haloalkyl, C_{3-12} cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R^{1a})(R^{1b}), -S(O)(NR^{1a})(R^{1b}), -C(O)R^{1c}, -S(O_2)R^{1c}, or -C(O)OR^{1d},

wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^6 is each optionally substituted with one to four Z^1, which may be the same or different;

R^7 is -H, C_{1-8}alkyl, C_{1-6} haloalkyl, C_{3-12}cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)N(R^{2a})(R^{2b}), -S(O)(NR^{2a})(R^{2b}), -C(O)R^{2c}, S(O_2)R^{2c}, or -C(O)OR^{2d},

wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^7 is each optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 20 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O or S;

each Z^1, Z^2, or Z^3 is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, =O, imino, -NO_2, -N_3, -CN, -O-R^{3a}, -C(O)-R^{3a}, -C(O)O-R^{3a}, -C(O)-N(R^{3a})(R^{3b}), -N(R^{3a})(R^{3b}), -N(R^{3a})$_2$(R^{3b})$^+$,-N(R^{3a})C(O)-R^{3b}, -N(R^{3a})C(O)O-R^{3b}, -N(R^{3a})C(O)N(R^{3b})(R^{3c}), -N(R^{3a})S(O_2)(R^{3b}), -NR^{3a}S(O_2)N(R^{3b})(R^{3c}), -NR^{3a}S(O_2)O(R^{3b}), -OC(O)R^{3a}, -OC(O)OR^{3a}, -OC(O)-N(R^{3a})(R^{3b}), -S-R^{3a}, -S(O)R^{3a}, -S(O)(NH)R^{3a}, -S(O_2)R^{3a}, -S(O_2)N(R^{3a})(R^{3b}), -S(O)(NR^{3a})R^{3b}, -S(O)(NR^{3a})N(R^{3b})(R^{3c}), -SF_5, or -Si(R^{3a})$_3$;

wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z^1, Z^2, or Z^3 is each optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6}

haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, =O, $-NO_2$, -CN, $-N_3$, $-O-R^{3a}$, $-C(O)R^{3a}$, $-C(O)O-R^{3a}$, $-C(O)N(R^{3a})(R^{3b})$, $-N(R^{3a})(R^{3b})$, $-N(R^{3a})_2(R^{3b})^+$, $-N(R^{3a})-C(O)R^{3b}$, $-N(R^{3a})C(O)O(R^{3b})$, $-N(R^{3a})C(O)N(R^{3b})(R^{3c})$, $-N(R^{3a})S(O)_2(R^{3b})$, $-N(R^{3a})S(O)_2-N(R^{3b})(R^{3c})$, $-N(R^{3a})S(O)_2O(R^{3b})$, $-OC(O)R^{3a}$, $-OC(O)OR^{3a}$, $-OC(O)-N(R^{3a})(R^{3b})$, $-S-R^{3a}$, $-S(O)R^{3a}$, $-S(O)(NH)R^{3a}$, $-S(O)_2R^{3a}$, $-S(O)_2N(R^{3a})(R^{3b})$, $-S(O)(NR^{3a})R^{3b}$, or $-Si(R^{3a})_3$;

wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is each optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, oxo, -OH, -CN, $-NO_2$, $-NH_2$, $-N_3$, -SH, $-O(C_{1-9}$ alkyl), $-O(C_{1-8}$ haloalkyl), $-O(C_{2-6}$ alkenyl), $-O(C_{2-6}$ alkynyl), $-O(C_{3-15}$ cycloalkyl), -O(heterocyclyl), $-O(C_{6-10}$ aryl), -O(heteroaryl), $-NH(C_{1-9}$ alkyl), $-NH(C_{1-8}$ haloalkyl), $-NH(C_{2-6}$ alkenyl), $-NH(C_{2-6}$ alkynyl), $-NH(C_{3-15}$ cycloalkyl), -NH(heterocyclyl), $-NH(C_{6-10}$ aryl), -NH(heteroaryl), $-N(C_{1-9}$ alkyl)$_2$, $-N(C_{1-8}$ haloalkyl)$_2$, $-N(C_{2-6}$ alkenyl)$_2$, $-N(C_{2-6}$ alkynyl)$_2$, $-N(C_{3-15}$ cycloalkyl)$_2$, -N(heterocyclyl)$_2$, $-N(C_{6-10}$ aryl)$_2$, -N(heteroaryl)$_2$, $-N(C_{1-9}$ alkyl)(C_{1-8} haloalkyl), $-N(C_{1-9}$ alkyl)(C_{2-6} alkenyl), $-N(C_{1-9}$ alkyl)(C_{2-6} alkynyl), $-N(C_{1-9}$ alkyl)(C_{3-15} cycloalkyl), -N(C_{1-9} alkyl)(heterocyclyl), $-N(C_{1-9}$ alkyl)(C_{6-10} aryl), $-N(C_{1-9}$ alkyl)(heteroaryl), $-C(O)(C_{1-9}$ alkyl), $-C(O)(C_{1-8}$ haloalkyl), $-C(O)(C_{2-6}$ alkenyl), $-C(O)(C_{2-6}$ alkynyl), $-C(O)(C_{3-15}$ cycloalkyl), -C(O)(heterocyclyl), $-C(O)(C_{6-10}$ aryl), -C(O)(heteroaryl), $-C(O)O(C_{1-9}$ alkyl), $-C(O)O(C_{1-8}$ haloalkyl), $-C(O)O(C_{2-6}$ alkenyl), $-C(O)O(C_{2-6}$ alkynyl), $-C(O)O(C_{3-15}$ cycloalkyl), -C(O)O(heterocyclyl), $-C(O)O(C_{6-10}$ aryl), -C(O)O(heteroaryl), $-C(O)NH_2$, $-C(O)NH(C_{1-9}$ alkyl), $-C(O)NH(C_{1-8}$ haloalkyl), $-C(O)NH(C_{2-6}$ alkenyl), $-C(O)NH(C_{2-6}$ alkynyl), $-C(O)NH(C_{3-15}$ cycloalkyl), -C(O)NH(heterocyclyl), $-C(O)NH(C_{6-10}$ aryl), -C(O)NH(heteroaryl), $-C(O)N(C_{1-9}$ alkyl)$_2$, $-C(O)N(C_{1-8}$ haloalkyl)$_2$, $-C(O)N(C_{2-6}$ alkenyl)$_2$, $-C(O)N(C_{2-6}$ alkynyl)$_2$, $-C(O)N(C_{3-15}$ cycloalkyl)$_2$, -C(O)N(heterocyclyl)$_2$, $-C(O)N(C_{6-10}$ aryl)$_2$, -C(O)N(heteroaryl)$_2$, $-NHC(O)(C_{1-9}$ alkyl), $-NHC(O)(C_{1-8}$ haloalkyl), $-NHC(O)(C_{2-6}$ alkenyl), $-NHC(O)(C_{2-6}$ alkynyl), $-NHC(O)(C_{3-15}$ cycloalkyl), -NHC(O)(heterocyclyl), $-NHC(O)(C_{6-10}$ aryl), -NHC(O)(heteroaryl), $-NHC(O)O(C_{1-9}$ alkyl), $-NHC(O)O(C_{1-8}$ haloalkyl), $-NHC(O)O(C_{2-6}$ alkenyl), $-NHC(O)O(C_{2-6}$ alkynyl), $-NHC(O)O(C_{3-15}$ cycloalkyl), -NHC(O)O(heterocyclyl), $-NHC(O)O(C_{6-10}$ aryl), -NHC(O)O(heteroaryl), $-NHC(O)NH(C_{1-9}$ alkyl), $-NHC(O)NH(C_{1-8}$ haloalkyl), $-NHC(O)NH(C_{2-6}$ alkenyl), $-NHC(O)NH(C_{2-6}$ alkynyl),

-NHC(O)NH(C_{3-15} cycloalkyl), -NHC(O)NH(heterocyclyl), -NHC(O)NH(C_{6-10} aryl), -NHC(O)NH(heteroaryl), -NHS(O)(C_{1-9} alkyl), -N(C_{1-9} alkyl)(S(O)(C_{1-9} alkyl), -S(C_{1-9} alkyl), -S(C_{1-8} haloalkyl), -S(C_{2-6} alkenyl), -S(C_{2-6} alkynyl), -S(C_{3-15} cycloalkyl), -S(heterocyclyl), -S(C_{6-10} aryl), -S(heteroaryl), -S(O)N(C_{1-9} alkyl)$_2$, -S(O)(C_{1-9} alkyl), -S(O)(C_{1-8} haloalkyl), -S(O)(C_{2-6} alkenyl), -S(O)(C_{2-6} alkynyl), -S(O)(C_{3-15} cycloalkyl), -S(O)(heterocyclyl), -S(O)(C_{6-10} aryl), -S(O)(heteroaryl), -S(O)$_2$(C_{1-9} alkyl), -S(O)$_2$(C_{1-8} haloalkyl), -S(O)$_2$(C_{2-6} alkenyl), -S(O)$_2$(C_{2-6} alkynyl), -S(O)$_2$(C_{3-15} cycloalkyl), -S(O)$_2$(heterocyclyl), -S(O)$_2$(C_{6-10} aryl), -S(O)$_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -S(O)$_2$NH(C_{1-9} alkyl), or -S(O)$_2$N(C_{1-9} alkyl)$_2$;

wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1b} is optionally substituted with one to three C_{1-9} alkyl, C_{1-8} haloalkyl, halogen, -OH, -NH_2, -O(C_{1-9} alkyl), -O(C_{1-8} haloalkyl), -O(C_{3-15} cycloalkyl), -O(heterocyclyl), -O(aryl), -O(heteroaryl), -NH(C_{1-9} alkyl), -NH(C_{1-8} haloalkyl), -NH(C_{3-15} cycloalkyl), -NH(heterocyclyl), -NH(aryl), -NH(heteroaryl), -N(C_{1-9} alkyl)$_2$, -N(C_{3-15} cycloalkyl)$_2$, -NHC(O)(C_{1-8} haloalkyl), -NHC(O)(C_{3-15} cycloalkyl), -NHC(O)(heterocyclyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)O(C_{1-9} alkyl), -NHC(O)O(C_{1-8} haloalkyl), -NHC(O)O(C_{2-6} alkynyl), -NHC(O)O(C_{3-15} cycloalkyl), -NHC(O)O(heterocyclyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)NH(C_{1-9} alkyl), S(O)$_2$(C_{1-9} alkyl), -S(O)$_2$(C_{1-8} haloalkyl), -S(O)$_2$(C_{3-15} cycloalkyl), -S(O)$_2$(heterocyclyl), -S(O)$_2$(aryl), -S(O)$_2$(heteroaryl), -S(O)(NH)(C_{1-9} alkyl), -S(O)$_2$NH(C_{1-9} alkyl), or -S(O)$_2$N(C_{1-9} alkyl)$_2$;

each R^{1a}, R^{1b}, R^{1c}, R^{1d}, R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{3a}, R^{3b}, and R^{3c} is independently -H, C_{1-9} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each R^{1a}, R^{1b}, R^{1c}, R^{1d}, R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{3a}, R^{3b}, and R^{3c} is each optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each aryl of the compound of Formula (I) unless otherwise specified is C_{6-10} aryl;

wherein each heteroaryl of the compound of Formula (I) unless otherwise specified is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S;

wherein each heterocyclyl of the compound of Formula (I) unless otherwise specified is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

3. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein the compound of Formula (I) is a compound of Formula (Ia):



(Ia).

or the compound of Formula (I) is a compound of Formula (Ib):



(Ib).

4. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein

R^1 is -H;

R^2 is -H or -F;

R^{21} is -H or -F;

R^3 is -H or -F;

R^{4a} and R^{4b} are each independently -H -F, or $-CH_3$;

Ring A is a cyclopentyl, cyclohexyl, cycloheptyl, cyclohexenyl, or tetrahydropyranyl ring;

n is 0, 1, or 2;

each R^5 is independently -F, -OH, $-CH_3$, $=CH_2$, $-CH_2$-OH, or -O-CH_3;

R^6 is -H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^6 is optionally substituted with one to four Z^1, which may be the same or different;

R^7 is -H, C_{1-8} alkyl, C_{1-6} haloalkyl, C_{3-12} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S;

each Z^1, Z^2, or Z^3 is independently deuterium, halogen, =O, -CN, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -O-R^{3a};

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, -CN, -O-R^{3a}, or -$S(O)_2R^{3a}$,

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -CN,

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1b} is unsubstituted;

each R^{3a} is independently -H, C_{1-9} alkyl, C_{6-10} aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

5. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein

R^1 is -H;

R^2 is -H or -F;

R^3 is -H or -F;

R^{4a} and R^{4b} are each independently -H -F, or -CH_3;

Ring A is a cyclopentyl, cyclohexyl, cyclohexenyl, or tetrahydropyranyl ring;

n is 0, 1, or 2;

each R^5 is independently -F, -OH, -CH_3, or -O-CH_3;

R^6 is -H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^6 is optionally substituted with one to four Z^1, which may be the same or different;

R^7 is -H, C_{1-8} alkyl, C_{1-6} haloalkyl, C_{3-12} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S;

each Z^1, Z^2, or Z^3 is independently deuterium, halogen, =O, -CN, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -O-R^{3a};

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, -CN, -O-R^{3a}, or -$S(O)_2R^{3a}$,

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -CN,

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1b} is unsubstituted;

each R^{3a} is independently -H, C_{1-9} alkyl, C_{6-10} aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

6. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 5, wherein

R^1 is -H;

R^2 is -H or -F;

R^3 is -H or -F;

R^{4a} and R^{4b} are each independently -H or -F;

Ring A is a cyclohexyl, cyclohexenyl, or tetrahydropyranyl ring;

n is 0;

R^6 is -H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^6 is optionally substituted with one to four Z^1, which may be the same or different;

R^7 is -H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocyclyl, C_{6-10} aryl, or heteroaryl,

wherein each alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 12 membered heterocyclyl having 0 to 3 additional heteroatoms each independently N, O, or S;

each Z^1, Z^2, or Z^3 is independently halogen, =O, -CN, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -O-R^{3a};

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of each Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently -D, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkoxyalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, -CN, -O-R^{3a}, or -$S(O)_2R^{3a}$;

wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halogen, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -CN,

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1b} is unsubstituted;

each R^{3a} is independently -H, C_{1-9} alkyl, C_{6-10} aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 12 membered heteroaryl having one to four heteroatoms each independently N, O, or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 20 membered heterocyclyl having one to four heteroatoms each independently N, O, or S.

7. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein

R^1 is -H;

R^2 is -H or -F;

R^{21} is -H or -F;

R^3 is -H or -F;

R^{4a} is -H, -F, or -CH_3, and R^{4b} is -H;

Ring A is  ;

n is 0, 1, or 2;

each R^5 is independently -F, -OH, $-CH_3$, $=CH_2$, $-CH_2$-OH, or -O-CH_3;

R^6 is -H or C_{1-6} alkyl optionally substituted with one Z^1, wherein Z^1 is unsubstituted;

R^7 is -H, C_{1-8} alkyl, C_{3-12} cycloalkyl, C_{6-10} aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur,

wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 7 membered heterocyclyl optionally having an additional N;

each Z^1, Z^2, or Z^3 is independently deuterium, halogen, =O, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-15} cycloalkyl, C_{6-10} aryl, heterocyclyl, heteroaryl or -O-R^{3a};

wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, halogen, -CN, or $-S(O)_2R^{3a}$;

wherein each alkyl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently halogen, C_{3-15} cycloalkyl, or C_{6-10} aryl,

wherein each cycloalkyl or aryl of Z^{1b} is unsubstituted;

each R^{3a} is independently C_{1-9} alkyl or C_{6-10} aryl, wherein each alkyl or aryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

8. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7, wherein

R^1 is -H;

R^2 is -H or -F;

R^3 is -H or -F;

R^{4a} is -H, -F, or $-CH_3$, and R^{4b} is -H;

Ring A is  ,  ,  ,  ,  , or  ;

n is 0, 1, or 2;

each R^5 is independently -F, -OH, $-CH_3$, or $-O-CH_3$;

R^6 is -H or C_{1-6} alkyl optionally substituted with one Z^1, wherein Z^1 is unsubstituted;

R^7 is -H, C_{1-8} alkyl, C_{3-12} cycloalkyl, C_{6-10} aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur,

wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 7 membered heterocyclyl optionally having an additional N;

each Z^1, Z^2, or Z^3 is independently deuterium, halogen, =O, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-15} cycloalkyl, C_{6-10} aryl, heterocyclyl, heteroaryl or -O-R^{3a};

wherein each alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently deuterium, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, halogen, -CN, or -$S(O)_2R^{3a}$;

wherein each alkyl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently halogen, C_{3-15} cycloalkyl, or C_{6-10} aryl,

wherein each cycloalkyl or aryl of Z^{1b} is unsubstituted;

each R^{3a} is independently C_{1-9} alkyl or C_{6-10} aryl, wherein each alkyl or aryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

9. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, wherein

R^1 is -H;

R^2 is -H or -F;

R^3 is -H or -F;

R^{4a} and R^{4b} are each -H;

Ring A is  ;

n is 0;

R^6 is -H or C_{1-6} alkyl optionally substituted with one Z^1, wherein Z^1 is unsubstituted;

R^7 is -H, C_{1-6} alkyl, C_{3-10} cycloalkyl, or heterocyclyl,

wherein each alkyl, cycloalkyl, or heterocyclyl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; or

R^6 and R^7 together with the nitrogen to which they are attached form a heterocyclyl, which is optionally substituted with one to four Z^3, which may be the same or different; wherein the heterocyclyl formed by R^6 and R^7 is 3 to 7 membered heterocyclyl optionally having an additional N;

each Z^1, Z^2, or Z^3 is independently halogen, =O, C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{3-15} cycloalkyl, heterocyclyl, C_{6-10} aryl, heteroaryl, or -O-R^{3a};

wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^1, Z^2, or Z^3 is optionally substituted with one to four Z^{1a}, which may be the same or different;

each Z^{1a} is independently C_{1-9} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, halogen, -CN, or -$S(O)_2R^{3a}$;

wherein each alkyl of Z^{1a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

each Z^{1b} is independently halogen, C_{3-15} cycloalkyl, or C_{6-10} aryl;

wherein each cycloalkyl or aryl of Z^{1b} is unsubstituted;

each R^{3a} is independently C_{1-9} alkyl or C_{6-10} aryl, wherein each alkyl or aryl of R^{3a} is optionally substituted with one to four Z^{1b}, which may be the same or different;

wherein each heteroaryl of the compound of Formula (I) or Formula (Ia) is 5 to 6 membered heteroaryl having one or two heteroatoms each independently N or S;

wherein each heterocyclyl of the compound of Formula (I) or Formula (Ia) is 3 to 7 membered heterocyclyl having one to two heteroatoms each independently N or O.

10. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2 and 4 to 9, wherein the compound of Formula (I) is a compound of Formula (IIa):



(IIa);

or wherein the compound of Formula (I) is a compound of Formula (IIb):



(IIb);

or wherein the compound of Formula (I) is a compound of Formula (IIc):



or wherein the compound of Formula (I) is a compound of Formula (IId):



(IId);

or wherein the compound of Formula (I) is a compound of Formula (IIe):



(IIe);

11. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, wherein the compound of Formula (I) is a compound of Formula (IIf):



(IIf);

or wherein the compound of Formula (I) is a compound of Formula (IIg):



(IIg);

or wherein the compound of Formula (I) is a compound of Formula (IIh):



(IIh);

or wherein the compound of Formula (I) is a compound of Formula (IIi):



(IIi).

12. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2 and 4 to 7, wherein the compound of Formula (I) is a compound of Formula (IIj):



(IIj).

or wherein the compound of Formula (I) is a compound of Formula (IIk):



(IIk);

13. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 3, 5, 7, 8, and 10 to 12, wherein R^{4a} is -F, or $-CH_3$.

14. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 5, 7, 8, and 10 to 13, wherein n is 1 or 2, and wherein each R^5 is independently -F, -OH, $-CH_3$, or $-O-CH_3$.

15. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 14, wherein R^6 is:

(a) -H; or

(b) unsubstituted C_{1-6} alkyl; or .

(c)

-CH_3 or  .

16. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 15, wherein R^7 is:

(a) C_{1-6} alkyl or C_{3-10} cycloalkyl, each optionally substituted with one or two halogen or C_{6-10} aryl of Z^2; or

(b) C_{1-6} alkyl or cyclohexyl, each optionally substituted with one or two -F or phenyl of Z^2; or

(c)



, , or ; or

(d): is 

, , or .

17. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 10, wherein the compound of Formula (I), (IIa), or (IId), is a compound of Formula (IIIa):



(IIIa).

18. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, 4 to 9, and 12, wherein the compound of Formula (I) or (IIk), is a compound of Formula (IIIa-1):



(IIIa-1).

19. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 9, wherein the compound of Formula (I) is a compound of Formula (IIIa-2):



(IIIa-2); or

wherein the compound of Formula (I) is a compound of Formula (IIIa-3):



(IIIa-3).

20. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 15 and 17 to 19, wherein R^7 is:

(a) -H, C_{1-8} alkyl, C_{3-12} cycloalkyl, C_{6-10} aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl of R^7 is optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently, deuterium, halogen, =O, -CN, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-10}

cycloalkyl, C_{6-10} aryl, 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, or-C(O)-R^{3a}, wherein R^{3a} is -H or unsubstituted C_{1-6} alkyl, wherein each C_{1-6} alkyl of Z^2 is optionally substituted with 1 to 3 Z^{1a}, wherein each Z^{1a} is independently cyano or C_{1-6} alkoxy; or

(b) is -H, C_{1-8} alkyl, C_{3-12} cycloalkyl, C_{6-10} aryl, 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen,oxygen, and sulfur, or 5 to 12 membered heteroaryl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl of R^7 is optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently, deuterium, halogen, =O, -CN, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, C_{6-10} aryl, or -C(O)-R^{3a}, wherein R^{3a} is -H or unsubstituted C_{1-6} alkyl, wherein each C_{1-6} alkyl of Z^2 is optionally substituted with 1 to 3 Z^{1a}, wherein each Z^{1a} is independently cyano or C_{1-6} alkoxy; or

(c) is -H, C_{1-6} alkyl, C_{3-12} cycloalkyl, or 4 to 12 membered heterocyclyl having a heteroatom selected from nitrogen and oxygen, wherein each alkyl, cycloalkyl or heterocyclyl of R^7 is optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently halogen, =O, C_{1-6} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, or -C(O)-R^{3a}, wherein R^{3a} is -H or unsubstituted C_{1-6} alkyl; or

(d) is -H, C_{1-8} alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxepanyl, dioxanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, (3aR,6aS)-hexahydro-1H-cyclopenta[c]furanyl, bicyclo[3.2.1]octyl, (1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, (3aR,6aS)-2-methyloctahydropentalenyl, (1R,5S)-6,6-dimethylbicyclo[3.1.0]hexyl, spiro[2.4]heptyl, 7,7-difluoro-spiro[3.5]nonanyl, (4s,7s)-1-oxaspiro[3.5]nonanyl, (4r,7r)-oxaspiro[3.5]nonanyl, oxabicyclo[2.2.1]heptanyl, 3-oxabicyclo[3.2.1]octanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, tetrahydrothiopyranyl, -2,3-dihydro-1H-indyl, chromane, or 4,5,6,7-tetrahydro-1H-indazolyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently deuterium, =O, -CN, $-CH_3$, $-CH_2-O-CH_3$, $-CH_2-CN$, $-O-CH_3$, $-O-CF_3$, $-CF_3$, $-O-C_2H_5$, $-O-C_3H_7$, $-C(O)-CH_3$, -F, cyclopropyl, phenyl, triazolyl, or pyridyl; or

(e) is -H, C_{1-8} alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxepanyl,

dioxanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, (3aR,6aS)-hexahydro-1H-cyclopenta[c]furanyl, bicyclo[3.2.1]octyl, (1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, (3aR,6aS)-2-methyloctahydropentalenyl, (1R,5S)-6,6-dimethylbicyclo[3.1.0]hexyl, spiro[2.4]heptyl, 7,7-difluoro-spiro[3.5]nonanyl, (4s,7s)-1-oxaspiro[3.5]nonanyl, (4r,7r)-oxaspiro[3.5]nonanyl, oxabicyclo[2.2.1]heptanyl, 3-oxabicyclo[3.2.1]octanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, tetrahydrothiopyranyl, -2,3-dihydro-1H-indyl, chromane, 4,5,6,7-tetrahydro-1H-indazolyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently deuterium, =O, -CN, $-CH_3$, $-CH_2-O-CH_3$, $-CH_2-CN$, $-O-CH_3$, $-O-CF_3$, $-CF_3$, $-O-C_2H_5$, $-O-C_3H_7$, $-C(O)-CH_3$, -F, cyclopropyl, or phenyl; or.

(f) is -H, C_{1-6} alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, oxetanyl, oxaspiro[3.3]heptyl, oxaspiro[3.5]nonyl, oxabicyclo[3.2.1]octyl, tetrahydrofuranyl, or tetrahydropyranyl, piperidyl, or tetrahydrothiopyranyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently =O, $-CH_3$, $-CF_3$, $-O-C_2H_5$, $-C(O)-CH_3$, or -F; or

(g) is -H, 





 ,  ,  ,  ,  ,

 ,  , or  ; or

(h) is -H,  ,  ,  ,  ,  ,  ,  ,  ,

 ,

 ,

 ,

 ,

,

 ,





(i) is -H,





21. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, 4 to 10 and 17, wherein the compound of Formula (I), (IIa), (IId) or (IIIa), is a compound of Formula (IVa):



(IVa)

wherein q is 1, 2, or 3.

22. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, 4 to 10, 17 and 21, wherein the compound of Formula (I), (IIa), (IId), (IIIa), or (IVa) is a compound of Formula (IVa-1):



(IVa-1); or

wherein the compound of Formula (I), (IIa), (IId), (IIIa), or (IVa) is a compound of Formula (IVa-2):



(IVa-2)

23. The compound or pharmaceutically acceptable salt thereof of claim 21, wherein q is 1 or 2.

24. The compound or pharmaceutically acceptable salt thereof of any one of claims 21 to 23, wherein Z^2 is:

(a) -O-R^{3a} , C_{3-15} cycloalkyl, 4 to 14 membered heterocyclyl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, C_{6-10} aryl, 5 to 14 membered heteroaryl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each Z^2 is optionally substituted with one to four Z^{1a}, which may be the same or different, wherein each Z^{1a} is independently deuterium, cyano, halogen, C_{1-6} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, or-$S(O)_2R^{3a}$, and each wherein each R^{3a} is independently C_{1-9} alkyl or C_{6-10} aryl, wherein each alkyl or aryl of R^{3a} optionally substituted with one to four halogen; or

(b) -O-R^{3a} , cyclopropyl, cyclobutyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, phenyl, naphthyl, thiazolyl, pyrazolyl, pyridyl, or pyrazinyl, each optionally substituted with 1 or 3 Z^{1a}, wherein each Z^{1a} is independently cyano, -F, -Cl, -O-CH_3, -CF_3, or phenyl, and wherein each R^{3a} is independently methyl, ethyl, or phenyl, wherein each phenyl of R^{3a} is optionally substituted with -Cl; or

(c) -O-R^{3a}, cyclopropyl, cyclobutyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, phenyl, naphthyl, thiazolyl, pyrazolyl, pyridyl, or pyrazinyl, each optionally substituted with 1 or 2 Z^{1a}, wherein each Z^{1a} is independently cyano, -F, -Cl, -OCH_3, -CF_3, and wherein each R^{3a} is independently methyl, ethyl, or phenyl, wherein each phenyl of R^{3a} is optionally substituted with -Cl; or

(d)





(e)





25. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, 4 to 10, and 17, wherein the compound of Formula (I), (IIa), (IId) or (IIIa), is a compound of Formula (IVb):



(IVb)

wherein each Z^2 may be the same or different.

26. The compound or pharmaceutically acceptable salt thereof of claim 25, wherein each Z^2, which may be the same or different, is independently:

(a) C_{1-6} alkyl, C_{3-15} cycloalkyl, 4 to 14 membered heterocyclyl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, C_{6-14} aryl, or C_{1-6} alkoxy, each optionally substituted with 1 or 3 Z^{1a}, wherein each Z^{1a} is independently halogen, cyano, =O, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, or C_{6-14} aryl; or

(b) C_{1-6} alkyl, C_{3-15} cycloalkyl, 4 to 14 membered heterocyclyl having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur, C_{6-14} aryl, or C_{1-6} alkoxy, each optionally substituted

with 1 or 3 Z^{1a}, wherein each Z^{1a} is independently halogen, cyano, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, C_{6-14} aryl; or

(c) C_{1-6} alkyl, C_{3-15} cycloalkyl, C_{6-14} aryl, or C_{1-6} alkoxy; or

(d) methyl, ethyl, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahyrdofuranyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, phenyl, or thiopyranyl, each optionally substituted with 1 or 3 Z^{1a}, wherein each Z^{1a} is independently -F, $-CH_3$, $-CHF_2$, -CN, =O, or cyclopropyl; or

(e) methy, ethy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahyrdofuranyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, or phenyl, each optionally substituted with 1 or 3 Z^{1a}, wherein each Z^{1a} is independently -F, $-CH_3$, $-CHF_2$, -CN, or cyclopropyl; or

(f)



(g)



(h)



27. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 10 wherein the compound of Formula (I), (IIa), or (IId), is a compound of Formula (IIIb):



(IIIb)

wherein each p or q, which may be the same or different, is independently 1, 2, or 3.

28. The compound or pharmaceutically acceptable salt thereof of claim 27, wherein p and q are each 1.

29. The compound or pharmaceutically acceptable salt thereof of claim 27 or 28, wherein each Z^1 or Z^2, which may be the same or different, is independently:

(a) -H, C_{6-10} aryl, or 4 to 10 membered heterocyclyl having 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each aryl or heterocyclyl of Z^1 or Z^2 is unsubstituted; or

(b) hydrogen, unsubstituted phenyl, or unsubstituted tetrahydropyranyl; or

(c)



30. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 10, wherein the compound of Formula (I), (IIa), or (IId) is a compound of Formula (IIIc):



(IIIc).

31. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein Z^3 is:

(a) -H, C_{6-10} aryl, or -O-R^{3a}, wherein R^{3a} is -H, C_{1-6} alkyl or C_{6-10} aryl, wherein the R^{3a} alkyl or aryl is each optionally substituted with halogen, C_{3-10} cycloalkyl, or C_{6-10} aryl; or

(b) methyl, phenyl, or -O-R^{3a}, wherein R^{3a} is methyl, ethyl, or phenyl, wherein the R^{3a} methyl or phenyl is each optionally substituted with -Cl, cyclopropyl, or phenyl; or

(c)



32. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 10 wherein the compound of Formula (I), (IIa), or (IId) is a compound of Formula (IIId):



(IIId).

33. The compound or pharmaceutically acceptable salt thereof of claim 32, wherein Z^3 is:

(a) C_{1-6} alkyl optionally substituted with one C_{6-10} aryl of Z^{1a}, wherein the C_{6-10} aryl of Z^{1a} is optionally substituted with one halogen of Z^{1b}; or

(b) methyl, optionally substituted with one phenyl of Z^{1a}, wherein the phenyl of Z^{1a} is optionally substituted with one -Cl of Z^{1b}; or

(c) 

.

34. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 10 wherein the compound of Formula (I), (IIb), or (IIe) is a compound of Formula (IIIe):



(IIIe).

35. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R^7 is

(a): C_{1-6} alkyl; or

(b): 
.

36. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 2, and 4 to 11, wherein the compound of Formula (I), (IIc), or (IIf) is a compound of Formula (IIIf):



(IIIf).

37. The compound or pharmaceutically acceptable salt thereof of claim 36, wherein R^7 is:

(a) C_{1-8} alkyl, C_{3-12} cycloalkyl, or 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each alkyl, cycloalkyl, or

heterocyclyl of R^7 is optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently, deuterium, halogen, C_{3-10} cycloalkyl, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, or 4 to 12 membered heterocyclyl having 1 to 2 heteroatoms each independently selected from nitrogen, oxygen, and sulfur, wherein each C_{1-6} alkyl of Z^2 is optionally substituted with 1 to 3 Z^{1a}, wherein each Z^{1a} is independently halogen or C_{1-6} alkoxy; or

(b) C_{1-8} alkyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, piperidyl, or tetrahydroindazolyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently, deuterium, -F, $-CH_3$, $-CHF_2$, $-CH_2-CHF_2$, $-CF_3$, CH_2-CF_3, $-O-CH_3$, $-O-CHF_2$, $-CH_2-O-CH_3$, $-O-C_3H_7$, cyclobutyl, oxetanyl, or tetrahydropyranyl, wherein each cyclobutyl, oxetanyl, or tetrahydropyranyl is optionally substituted with 1 to 3 -F; or

(c) C_{1-8} alkyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]heptanyl, spiro[3.5]nonanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, or piperidyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently, deuterium, -F, $-CH_3$, $-CHF_2$, $-CH_2-CHF_2$, $-CF_3$, CH_2-CF_3, $-O-CH_3$, $-O-CHF_2$, $-CH_2-O-CH_3$, $-O-C_3H_7$, cyclobutyl, oxetanyl, or tetrahydropyranyl, wherein each cyclobutyl, oxetanyl, or tetrahydropyranyl is optionally substituted with 1 to 3 -F; or

(d) C_{3-12} cycloalkyl optionally substituted with 1 to 3 halogen; or

(e) cyclohexyl optionally substituted with 1 to 3 -F; or

(f) 



, or ; or

(g) 

(h) 

38. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 9, wherein R^1 is deuterium; and/or

R^2 is -H or -F; and/or

R^3 is -H or -F.

39. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, 10 to 16, and 20, wherein R^{4a} and R^{4b} are each hydrogen.

40. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) is a compound of Formula (V):



,

(V)

wherein

R^2 is -H or -F;

R^{21} is -H or -F;

R^3 is -H or -F;

R^7 is C_{1-8} alkyl or C_{3-12} cycloalkyl,

wherein each alkyl or cycloalkyl of R^7 is optionally substituted with one to four Z^2, which may be the same or different; and

each Z^2 is independently deuterium, halogen, C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{6-10} aryl.

41. The compound or pharmaceutically acceptable salt thereof of claim 40, wherein the compound of Formula (V) is a compound of Formula (Va):



,

(Va)

42. The compound or pharmaceutically acceptable salt thereof of claim 40 or 41, wherein R^2 is -H; R^{21} is -H; and R^3 is -H or -F.

43. The compound or pharmaceutically acceptable salt thereof of any one of claims 40 to 42, wherein R^7 is:

(a) C_{1-8} alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[2.3]hexyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, bicyclo[3.2.1]octyl, (1R,5S)bicyclo[3.1.0]hexyl, (1R,5S)bicyclo[3.2.0]heptyl, spiro[2.4]heptyl, each optionally substituted with 1 to 3 Z^2, which may be the same or different, wherein each Z^2 is independently deuterium, -CH_3, -C_2F, -CHF_2, -CF_3, -F, or phenyl; or

(b) C_{1-3} alkyl or cyclohexyl, each optionally substituted with 1 to 2 Z^2, which may be the same or different, wherein each Z^2 is independently -F or phenyl; or

(c) 



(d) 



44. The compound or pharmaceutically acceptable salt thereof of claim 40, wherein the compound is




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

or

.

45. The compound or pharmaceutically acceptable salt thereof of claim 40, wherein the compound is


,

,

,

,

,


,

,

,

,




,
or

.

46. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula (I) is a compound of Formula (VI):


,

(VI)

wherein

R^7 is C_{3-12} cycloalkyl, optionally substituted with one to four Z^2, which may be the same or different; and

each Z^2 is independently deuterium, halogen, C_{1-3} alkyl, C_{1-3} haloalkyl.

47. The compound or pharmaceutically acceptable salt thereof of claim 46, wherein the compound of Formula (VI) is a compound of Formula (VIa):



(VIa)

48. The compound or pharmaceutically acceptable salt thereof of claim 46 or 47, wherein R^7 is cyclohexyl optionally substituted with 1 to 4 Z^2, which may be the same or different, wherein each Z^2 is independently deuterium, $-CH_3$, $-C_2F$, $-CHF_2$, $-CF_3$, or -F.

49. The compound or pharmaceutically acceptable salt thereof of claim 46, wherein the compound is














,

,

,

,

,


,

,

,

,

,

,


,

,

, or

.

50. The compound or pharmaceutically acceptable salt thereof of claim 46, wherein the compound is


,

,

,

,

,

,

,

,


,

, or

.

51. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10 and 17, wherein the compound is


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

or .

52. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, and 17, wherein the compound is


,

,

,

,

,

,



















,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

, or

.

53. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 12, or 18, wherein the compound is


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

, or

.

54. The compound or pharmaceutically acceptable salt thereof of claim 1 or 10, wherein the compound is


,

,

,

,

,

,


,

,

,

,

,

,

or

.

55. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, and 27, wherein the compound is


,

,

,

,


,

, or

.

56. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, and 30, wherein the compound is


,

,

,

,

,

, or

.

57. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, and 34, wherein the compound is



.

58. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, and 36, wherein the compound is



,



, or



.

59. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, 11, and 36, wherein the compound is



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

 or  .

60. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, 11, and 36, wherein the compound is

 ,  ,

 ,  ,

 ,  ,

 ,  ,

 ,  ,


, 
,


, or 
.

61. The compound or pharmaceutically acceptable salt thereof of claim 1 or 11, wherein the compound is


, 
, or


.

62. The compound or pharmaceutically acceptable salt thereof of claim 1 or 12, wherein the compound is


.

63. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10, 18, and 40, wherein the compound is


,

,

,

,

,

,

, or

.

64. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 3, 10, 18, 19, and 40, wherein the compound is


,

, or

.

65. The compound or pharmaceutically acceptable salt thereof of any one of claims 1, 10 and 11, wherein the compound is


,

,

,

,

,

, or

.

66. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1 to 65, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

67. The pharmaceutical composition of claim 66, further comprising an additional therapeutic agent.

68. Use of a therapeutically effective amount of a compound of any one of claims 1 to 65, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claims 66 or 67 in the manufacture of a medicament for treating an IKFZ2 protein associated disease or condition.

69. The use of claim 68, wherein the IKFZ2 associated disease or condition is cancer.

70. The use of claim 69, wherein the cancer is:

(a) a hematological cancer selected from acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), B-cell ALL, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), undifferentiated leukemia, small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), Waldestrom's macroglobulinemia (WM)) and multiple myeloma (MM); or

(b) a solid tumor and is selected from lung cancer, colorectal cancer, stomach cancer, renal cancer, ovarian cancer, testicular cancer, uterine cancer, urinary bladder cancer, breast cancer, prostate cancer, cervical cancer, pancreatic cancer and head and neck cancer.

71. The use of any one of claims 68 to 70, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in combination with an additional therapeutic agent or therapeutic modality.

72. The pharmaceutical composition of claim 67 or the use of claim 71, wherein the additional therapeutic agent or additional therapeutic modality comprises one, two, three, or four additional therapeutic agents and/or therapeutic modalities.

73. The pharmaceutical composition of claim 67 or 72, or the use of claim 71 or 72, wherein the additional therapeutic agent or therapeutic modalities are selected from an immune checkpoint modulator, an antibody-drug conjugate (ADC), an antiapoptotic agent, a targeted anticancer therapeutic, a chemotherapeutic agent, surgery, or radiation therapy.

74. The pharmaceutical composition or use of claim 73, wherein the immune checkpoint modulator is selected from an anti-PD-(L)1 antibody, an anti-TIGIT antibody, an anti-CTLA4 antibody, an anti-CCR8 antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, a CD47 inhibitor, a DGKα inhibitor, an HPK1 inhibitor, a FLT3 agonist, an adenosine receptor antagonist, a CD39 inhibitor, a CD73 inhibitor, an IL-2 variant (IL-2v), and a CAR-T cell therapy.

75. The pharmaceutical composition or use of claim 74, wherein:

(a) the anti-PD-(L)1 antibody is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, spartalizumab, atezolizumab, avelumab, durvalumab, cosibelimab, sasanlimab, tislelizumab, retifanlimab, balstilimab, toripalimab, cetrelimab, genolimzumab, prolgolimab,

lodapolimab, camrelizumab, budigalimab, avelumab, dostarlimab, envafolimab, sintilimab, and zimberelimab; or

(b) the anti-TIGIT antibody is selected from tiragolumab, vibostolimab, domvanalimab, AB308, AK127, BMS-986207, and etigilimab; or

(c) the anti-CTLA4 antibody is selected from ipilimumab, tremelimumab, and zalifrelimab; or

(d) the CD47 inhibitor is selected from magrolimab, letaplimab, lemzoparlimab, AL-008, RRx-001, CTX-5861, FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, and Q-1801; or

(e) the adenosine receptor antagonist is etrumadenant (AB928), taminadenant, TT-10, TT-4, or M1069; or

(f) the CD39 inhibitor is TTX-030; or

(g) the CD73 inhibitor is quemliclustat (AB680), uliledlimab, mupadolimab, ORIC-533, ATG-037, PT-199, AK131, NZV930, BMS-986179, or oleclumab; or

(h) the IL-2v is aldesleukin (Proleukin), bempegaldesleukin (NKTR-214), nemvaleukin alfa (ALKS-4230), THOR-202 (SAR-444245), BNT-151, ANV-419, XTX-202, RG-6279 (RO-7284755), NL-201, STK-012, SHR-1916, or GS-4528; or

(i) the ADC is selected from sacituzumab govitecan, datopotamab deruxtecan, enfortumab vedotin, and trastuzumab deruxtecan; or

(j) the additional therapeutic agent is selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, GS-9911, GS-1811 (JTX-1811), quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, axicabtagene ciloleucel and brexucabtagene autoleucel.